cisplatin + doxorubicin + floxuridine

This is a combination chemotherapy regimen consisting of three cytotoxic agents—cisplatin, doxorubicin, and floxuridine. Each drug has a distinct mechanism of action targeting cancer cells through different pathways. Cisplatin is a platinum-based compound that forms DNA crosslinks, leading to apoptosis. Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. Floxuridine is an antimetabolite that inhibits thymidylate synthase after conversion to 5-fluorouracil in the body, disrupting DNA synthesis. This combination has been studied primarily for hepatic arterial infusion (HAI) therapy in nonresectable hepatocellular carcinoma (HCC) confined to the liver[2][5]. The regimen aims to maximize tumor response by leveraging synergistic effects among the drugs while managing toxicity profiles.